Drug intelligence / Profile preview

GFH018 + toripalimab

Development stage: Unknown
Lead developer: GenFleet Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **GFH018**, a small molecule inhibitor targeting the TGF-βRI kinase, which blocks TGF-β signaling to inhibit tumor growth and modulate the tumor immune microenvironment. **Toripalimab** is a PD-1 inhibitor used to enhance immune responses against tumors. The combination is being studied for its potential to synergistically inhibit tumor growth in advanced solid tumors, particularly in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Targets

PDCD1 (Programmed cell death protein 1 receptor)TGFBR1

Beyond the preview

Go deeper on GFH018 + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GFH018 + toripalimab.

Explore the full profile